Price
$30.11-0.95%Social Signal Score
Analyst Ratings
23 analystsRevenue
$3.10B+128.06%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Deepak S. Nath
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 18,362
- Beta
- 0.69
- Country
- GB
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 3.76
Financials
Revenue
$3.10B+128.1%Net Income
$303.00M+64.7%EBITDA
$748.00M+117.4%Free Cash Flow
$260.00M+300.0%EPS (diluted)
$0.70+79.5%Shares Outstanding (diluted)
430.40M-54.4%Operating Expenses
$1.75BCash & Debt
$754.00MReturn of Capital
$321.00MRevenue by Segment (annual)
$6.16BDividend per Share
$0.31Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $6.16B | $625.00M | $1.46 |
| 2024 | $5.81B | $412.00M | $0.94 |
| 2023 | $5.55B | $263.00M | $1.20 |
| 2022 | $5.21B | $223.00M | $0.50 |
| 2021 | $5.21B | $524.00M | $1.20 |
| 2020 | $4.56B | $448.00M | $1.02 |
| 2019 | $5.14B | $600.00M | $1.38 |
| 2018 | $4.90B | $663.00M | $1.52 |
| 2017 | $4.76B | $767.00M | $1.76 |
| 2016 | $4.67B | $784.00M | $1.76 |
| 2015 | $4.63B | $410.00M | $0.92 |
| 2014 | $4.62B | $501.00M | $1.12 |
| 2013 | $4.35B | $556.00M | $1.24 |
| 2012 | $4.14B | $729.00M | $1.62 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from SNN's reported EPS growth of -0.8% a year over 13 years.
- EPS in 5 years
- $1.39
- Implied price
- $30.48
- Return from $26.42
- 2.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $15.15 — -42.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 16 | 19 | 22 | 25 | 28 |
|---|---|---|---|---|---|
| -10.8% | -13.2% | -10.1% | -7.5% | -5.1% | -2.9% |
| -5.8% | -8.3% | -5.1% | -2.3% | 0.2% | 2.5% |
| -0.8% | -3.5% | -0.1% | 2.9% | 5.6% | 8.0% |
| 4.2% | 1.4% | 5.0% | 8.1% | 10.9% | 13.4% |
| 9.2% | 6.3% | 10.0% | 13.3% | 16.2% | 18.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
150+400.00%Social Signal Score
Mentions (11)
- Newsglobenewswire.com·6h ago·Neutral
…za en Europa el innovador implante de reparación de cartílago CARTIHEAL™ AGILI-C™, que será protagonista en el Congreso ICRS de Portugal Smith+Nephew (LSE: SN, NYSE: SNN), compañía global de tecnología médica, anuncia hoy que su innovador implante de reparación de cartílago CARTIHEAL AGILI-C ya está disponible para su comercialización en Europa. El implante CARTIHEAL ocupará un lugar destacado en el Congreso de la Sociedad International de Regeneración de Cartílago & Preservación Articular (ICRS…
View source ↗ - Newsglobenewswire.com·6h ago·Positive
…ropa CARTIHEAL™ AGILI-C™, l'innovativo impianto per la riparazione della cartilagine, che sarà presentato all'ICRS Summit in Portogallo. Smith+Nephew (LSE: SN, NYSE: SNN) azienda di tecnologia medica, annuncia il lancio commerciale in Europa di CARTIHEAL AGILI-C, l'innovativo impianto per la riparazione della cartilagine. La tecnologia sarà presentata all'International Cartilage Regeneration & Joint Preservation Society (ICRS) Summit, che si terrà a Porto, in Portogallo, dall'8 al 10 ottobre.
View source ↗ - Newsglobenewswire.com·6h ago·Negative
Smith+Nephew's revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that its innovative CARTIHEAL AGILI-C Cartilage Repair Implant is now commercially available in Europe. The CARTIHEAL Implant will take center stage at this week's International Cartilage Regeneration & Joint Preservation Society (ICRS) Summit in Porto, Portugal from October …
View source ↗ - Newszacks.com·5d ago·Neutral
Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care SNN expands its trauma portfolio with the EVOS PELVIC System, targeting complex pelvic and acetabular fracture procedures in the United States.
View source ↗ - Newsglobenewswire.com·12d ago·Neutral
…e management The All-in-one system combines plates, cannulated screws and specialized instrumentation to streamline complex pelvic surgery Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of the EVOS PELVIC Plating System, the next evolution of the EVOS plating platform designed to address the unique challenges of pelvic and acetabular surgery. EVOS PELVIC System is built on the proven principles of the EVOS platform that has become a trusted cho…
View source ↗ - Newsglobenewswire.com·12d ago·Neutral
…e management The All-in-one system combines plates, cannulated screws and specialized instrumentation to streamline complex pelvic surgery Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of the EVOS PELVIC Plating System, the next evolution of the EVOS plating platform designed to address the unique challenges of pelvic and acetabular surgery. EVOS PELVIC System is built on the proven principles of the EVOS platform that has become a trusted cho…
View source ↗ - Newsglobenewswire.com·15d ago·Negative
Smith+Nephew to showcase leading shoulder technologies for joint repair and reconstruction at ICSES 2026 Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will highlight a suite of advanced solutions for shoulder repair and reconstruction at the International Congress for Shoulder and Elbow Surgery (ICSES) in Vancouver from September 22-25. Surgeons are invited to visit the Smith+Nephew booth during ICSES to learn more about the following technologies: TE…
View source ↗ - Newsgurufocus.com·21d ago·Positive
Is It Too Late to Buy Smith & Nephew PLC (SNN) After 3.3% Rally? GF Value Says Undervalued On September 14, 2026, Smith and Nephew PLC (SNN) shares rose 3.3% to a current price of $28.40. The stock has experienced a 52-week range between $27.23 and $37.
View source ↗ - Newszacks.com·47d ago·Neutral
SNN Advances Surgical Robotics Through Imperial College Partnership Smith+Nephew's five-year Imperial College London partnership targets less invasive robotic surgery and could speed research into clinical use.
View source ↗ - Newsglobenewswire.com·49d ago·Neutral
Smith+Nephew and Imperial College London launch centre to accelerate innovation in surgical robotics Smith+Nephew and Imperial College London have launched a five-year partnership to deliver research for robotic surgery for musculoskeletal conditions.
View source ↗ - Newsmarketbeat.com·58d ago·Negative
Smith & Nephew SNATS Q2 Earnings Call Highlights Smith & Nephew SNATS NYSE: SNN reported second-quarter underlying revenue growth of 1.6%, below management's expectations, as continued strength in Sports Medicine and ENT was offset by weakness in U.S. Orthopaedics and Advanced Wound Bioactives.
View source ↗
Earnings
Tue, Feb 23(in 5 months)
Consensus estimate $1.21 per share
Typical surprise +0.7% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$0.95 vs $0.94beat
- Mon, Mar 2$1.18 vs $1.16beat
- Tue, Aug 5$0.86 vs $0.79beat
- Tue, Feb 25$0.94 vs $0.92beat
- Thu, Oct 31$0.50 vs $0.80miss
- Thu, Aug 1$0.75 vs $0.79miss
Estimates and results for SNN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
- Alan Armstrongsenate · disclosed Jul 21, 2026 (113d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (65d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (57d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (34d later)Sell$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2022 (41d later)Sell$50,001 - $100,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2022 (41d later)Sell$50,001 - $100,000
- Michael T. McCaulhouse · TX10 · disclosed Jun 14, 2022 (40d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jun 14, 2022 (40d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Feb 23, 2022 (26d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Feb 23, 2022 (26d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jan 27, 2022 (44d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Mar 30, 2021 (32d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Mar 30, 2021 (32d later)Buy$1,001 - $15,000
- Thomas Charles MacArthurhouse · NJ03 · disclosed Dec 6, 2018 (50d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.